4SC AG RPE
Was ist das RPE von 4SC AG?
RPE von 4SC AG ist €53.619k
Was ist die Definition von RPE?
Umsatz pro Mitarbeiter (RPE) ist der Umsatz geteilt durch die Anzahl der Mitarbeiter einer Organisation.
RPE von Unternehmen in Health Care Sektor auf XETRA im Vergleich zu 4SC AG
Was macht 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Unternehmen mit rpe ähnlich 4SC AG
- Jumia Technologies AG hat RPE von $53.468k
- LSL Property Services Plc hat RPE von £53.511k
- Neovasc hat RPE von $53.549k
- Stanley Furniture hat RPE von $53.560k
- VR Education Plc hat RPE von €53.618k
- City of London plc hat RPE von £53.618k
- 4SC AG hat RPE von €53.619k
- Greenpro Capital hat RPE von $53.672k
- Xinyang Maojian hat RPE von HKD$53.752k
- I.Céram SA hat RPE von €53.842k
- Génomic Vision SA hat RPE von €53.852k
- Profound Medical hat RPE von $53.973k
- Nikola hat RPE von $54.018k